Source:

Escherichia coli.

Molecular Weight:

7.9 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids.

Purity:

>97% by SDS-PAGE and HPLC analyses.

Biological activity:

Fully biologically active when compared to standard. Determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha, corresponding to a Specific Activity of ＞100 IU/mg.

AA Sequence:

LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA

Endotoxin:

Less than 1EU/g of rvMIP-2 as determined by LAL method.

Formulation:

Lyophilized from a 0.2m filtered concentrated solution in 20mM PB, pH 7.4, 150mM NaCl.

Background:

Viral MIP-2 cDNA encodes a 94 amino acid residue precursor protein with a 23 aa residue signal peptide that is cleaved to yield a 71 aa residue mature protein. Among human chemokines, vMIP-2 is most closely related to MIP-1α, sharing approximately 41% amino acid sequence identity. At the amino acid sequence level, vMIP-1 and vMIP-2 also share 48% identity. vMIP-1 and vMIP-2 are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. vMIP-2 binds to the CCR3 chemokine receptor through which eotaxin and other β chemokines activate eosinophils. vMIP-2 has been shown to activate and chemoattract human eosinphils.

Usage:

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.

Storage:

This lyophilized preparation is stable for several weeks at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles.